AT101
Advanced CAR-T therapy targeting CD19-expressing hematologic cancers with enhanced efficacy and breakthrough treatment potential.
CAR-T treatment for hematologic cancer expressing CD19
AT101 is a type of immunotherapy developed using CAR-T technology for the treatment of blood cancers expressing CD19.
Unique Humanized Antibody Technology
AbClon utilized the NEST discovery platform to derive a unique humanized antibody (compared to conventional antibodies targeting the FMC63 site of CD19). Our antibody with its unique mode of action demonstrates stronger therapeutic effects compared to existing CAR-T treatments and represents a new hope for patients who do not respond to current FMC63-based CAR-T treatments.
AT101 Anticancer Efficacy
The following data demonstrates the significant anticancer effects of AT101 CAR-T cells against B cell-derived cancer cells in preclinical studies, showing superior efficacy compared to conventional treatments.
B cell-derived lymphoma cell studies
| Day | No treat | T cell | CAR-T cell |
|---|---|---|---|
| 0 day |  |  |  |
| 7 days |  |  |  |
| 14 days | — |  |  |
| 21 days | — |  |  |
| 28 days | — |  |  |
B cell-derived leukemia cell studies
| Day | No treat | T cell | CAR-T cell |
|---|---|---|---|
| 0 day |  |  |  |
| 7 days |  |  |  |
| 14 days | — |  |  |
| 21 days | — |  |  |
| 28 days | — |  |  |
Research Outcome
The data clearly demonstrates that AT101 CAR-T cells effectively eliminate both B cell-derived lymphoma and leukemia cells over time, showing significant therapeutic potential for treating CD19-expressing hematologic cancers with higher efficacy than traditional approaches.
Learn more about our CAR-T Platform
Discover how TCT Health Technology is revolutionizing cancer treatment through advanced cell and gene therapy.
Back to CAR-T Platform